Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.

Molecular cancer therapeutics·2026
Same author

p21<sup>+</sup>TREM2<sup>+</sup> senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease.

Nature aging·2026
Same author

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes.

NAR cancer·2026
Same author

Endothelial cell MHC molecules are necessary and sufficient to reject 3D-printed human skin grafts in an advanced human immune system mouse.

bioRxiv : the preprint server for biology·2025
Same author

Mosaic pattern: lung functional heterogeneity at the alveolus level.

bioRxiv : the preprint server for biology·2025
Same author

Glycerol-3-phosphate activates ChREBP, FGF21 transcription and lipogenesis in citrin deficiency.

Nature metabolism·2025
Same journal

Editor's Note: Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-like Growth Factor I Receptor Monoclonal Antibody.

Molecular cancer therapeutics·2026
Same journal

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Molecular cancer therapeutics·2026
Same journal

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Molecular cancer therapeutics·2026
Same journal

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.

Molecular cancer therapeutics·2026
Same journal

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same journal

Concurrent inhibition of ICMT and RAF/MEK suppresses RAC1P29S-driven MAPK-pathway-inhibitor resistance in BRAFV600E melanoma by regulating TAZ activity.

Molecular cancer therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.5K

Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors.

Matthew A Murray1,2, Katelyn J Noronha3, Yazhe Wang4

  • 1Department of Therapeutic Radiology, Yale University, New Haven, Connecticut.

Molecular Cancer Therapeutics
|May 1, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces nanoparticle-encapsulated NAMPT inhibitors delivered via convection-enhanced delivery for treating gliomas with defective NAD+ metabolism, improving efficacy and reducing toxicity.

More Related Videos

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
07:25

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment

Published on: March 1, 2024

2.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.5K

Related Experiment Videos

Last Updated: Jun 27, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.5K
Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
07:25

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment

Published on: March 1, 2024

2.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.5K

Area of Science:

  • Neuro-oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Primary central nervous system tumors, including glioblastomas (GBMs), present treatment challenges due to the blood-brain barrier and complex mutations.
  • Specific mutations in gliomas lead to epigenetic changes, including silencing of the nicotinic acid phosphoribosyl transferase (NAPRT) gene, creating a vulnerability to NAMPT inhibitors.
  • Systemic administration of NAMPT inhibitors (NAMPTi) shows promise but is limited by dose-limiting toxicities like bone marrow and retinal toxicity.

Purpose of the Study:

  • To develop and evaluate a novel therapeutic strategy for NAPRT-silenced GBMs.
  • To investigate the use of nanoparticle (NP)-encapsulated NAMPT inhibitors delivered via convection-enhanced delivery (CED).
  • To assess the efficacy and toxicity profile of this novel approach compared to systemic administration.

Main Methods:

  • Formulation of GMX1778 (a NAMPTi) into degradable polymer nanoparticles (NPs).
  • Evaluation of NP-encapsulated GMX1778's potency, drug release kinetics, and anticancer activity in vitro and in vivo.
  • Administration of NP-encapsulated GMX1778 via CED in intracranial GBM xenograft models in mice.

Main Results:

  • NP-encapsulated GMX1778 retained potency for NAMPT inhibition and anticancer activity, with sustained drug release.
  • CED of NP-encapsulated GMX1778 demonstrated reduced retinal toxicity compared to systemic administration.
  • CED of NP-encapsulated GMX1778 significantly delayed tumor growth and extended survival in mice with intracranial GBM xenografts.

Conclusions:

  • CED of NP-encapsulated NAMPT inhibitors represents a promising strategy for treating gliomas with defects in NAD+ metabolism.
  • This approach has the potential to significantly improve the therapeutic index and efficacy of NAMPT inhibitors for brain tumors.
  • Further development of this localized drug delivery system could offer a more effective treatment option for challenging brain malignancies.